Systems and methods for treating coronavirus
US-2024131003-A1 · Apr 25, 2024 · US
US9758472B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9758472-B2 |
| Application number | US-201314104235-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 12, 2013 |
| Priority date | Jun 30, 2009 |
| Publication date | Sep 12, 2017 |
| Grant date | Sep 12, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Non-lactone carbocyclic and heterocyclic antagonists and agonists of bacterial quorum sensing. Pharmaceutical composition containing antagonists. Methods employing antagonists and agonists for modulation of quorum sensing. Compounds are exemplified by those of formula: A-[Z] n -L1-[Y] q -W-[V] m -L2-HG, where A is an acyclic aliphatic group, and HG is an optionally substituted phenyl group. Compounds include those where m and n are both 0, W is —NH—, Y is present and is —CO—CH 2 —CO—, and L1 and L2 independently are —[CH 2 ] p1 — and —[CH 2 ] p2 —, where p1 and p2, independently, are 0 or integers ranging from 1-10.
Opening claim text (preview).
We claim: 1. A compound having formula: A-CO—CH 2 —CO—NH—HG wherein A is an unsubstituted alkyl group having 9 or 10 carbon atoms and HG is an unsubstituted phenyl group. 2. The compound of claim 1 wherein A is an unsubstituted straight-chain alkyl group having 9 carbon atoms. 3. A compound selected from: 4. A pharmaceutical composition comprising a quorum sensing antagonist of claim 1 in an amount effective for obtaining a therapeutic effect and a pharmaceutically acceptable carrier. 5. The composition of claim 4 further comprising an antimicrobial compound, an antibacterial compound, an antiviral agent or an antibiotic, other than a quorum sensing antagonist. 6. A method for inhibiting quorum sensing bacteria which comprising the step of contacting the quorum sensing bacteria with an amount of a quorum sensing compound of claim 1 effective for inhibition of quorum sensing. 7. The method of claim 6 wherein bacterial biofilm formation is disrupted which comprises the step of contacting the biofilm or an environment containing the biofilm with the compound of claim 1 .
linked by a chain containing hetero atoms as chain links · CPC title
having carbon atoms of carboxamide groups and keto groups bound to the same carbon atom, e.g. acetoacetamides · CPC title
Acylated on said nitrogen atom · CPC title
Indoles, e.g. pindolol · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.